Navigation Links
Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide
Date:5/16/2011

WASHINGTON, May 16, 2011 /PRNewswire/ -- A poster entitled, "Time to Progression in Patients with Prostate Cancer: A Comparison of Continuous Degarelix versus Degarelix Following Leuprolide Treatment," is being presented at the American Urological Association 2011 meeting by E. David Crawford, MD, head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center in Denver, and lead study investigator. The full manuscript has just been accepted and will be published in the September 2011 issue of the Journal of Urology.  Other investigators for the study, sponsored by Ferring Pharmaceuticals Inc., included J.W. Moul, N. Shore, E. van der Meulen, and B.E. Persson.

These latest PSA results were observed in the 5-year extension study portion (CS21A) of a pivotal one-year, open-label, randomized phase III trial (CS21)  that evaluated the efficacy of FIRMAGON, a gonadotropin-releasing hormone (GnRH) antagonist, and leuprolide, a luteinizing hormone-releasing hormone (LHRH) agonist, and formed the primary basis of the approval of FIRMAGON for advanced prostate cancer.    

After one year, 384 patients entered CS21A and 134 who had received leuprolide were re-randomized to receive FIRMAGON.  The purpose of the extension study was to evaluate the safety and tolerability during long-term treatment with once-monthly injections of FIRMAGON 80 mg in patients with prostate cancer.  Exploratory efficacy endpoints were evaluated and included: serum levels of PSA over time, cumulative probability of no PSA failure, serum levels of testosterone over time, cumulative probability of testosterone level maintained at less than or equal to 0.5 ng/dL from Day 28 in CS21 and onwards, and serum levels of testosterone, PSA, LH, and FSH from the time of switch from leuprolide to degarelix.

Both the cumulative probability of no PSA failure and the cumulative probability of testosterone levels below c
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
2. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
3. Dr. Brad Vince, with Vince and Associates Clinical Research, Presents at the Exploratory Development World Congress 2009
4. PRA International: Participating Sponsor for Exploratory Clinical Development World in London
5. BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
6. Shionogi Inc. Announces Publication of Data in Pediatrics Demonstrating Efficacy of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets as Add-On Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
7. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
8. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
9. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
10. Deston Therapeutics Stands By Safety and Efficacy of Auralgan After FDA Action
11. Independent Clinical Research Confirms Clinical Efficacy and Cost-Effectiveness of the SurgiCount Safety-Sponge® System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... BEIJING, June 14, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... Mr. Xiaodong Wu, Chairman and Chief Executive Officer of ... of the Company,s American Depositary Shares ("ADSs") in the ...
... June 13, 2011 Tengion, Inc. (Nasdaq: ... trial of the Company,s lead clinical product candidate, the ... a urinary diversion following bladder removal (cystectomy). Tengion is ... approach as part of its ongoing clinical trial of ...
Cached Medicine Technology:China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 3Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 4
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... Delhi: The common cold may cause uncommon ailments if neglected, ... common cold because we have always thought it is harmless. ... left untreated. It could also negatively impact vision or cause ... is a surge in cases of chronic sinusitis because of ...
... the heart in their mouth when they read this bit. Genes ... attack have finally been identified by scientists. ,The ... of Britons carry a particular gene which doubles their chances of ... the form of making healthy lifestyle choices that may help cut ...
... While the field of transplantation is quite young, substantial advancements ... supply of organs and the demand for them. The ... system through a point system based primarily on wait time, ... occurs, the kidney is offered to the person at the ...
... risk for alcohol dependence are more likely to choose a ... University School of Medicine in St. Louis. That doesn't ... problem drinkers. ,Alcoholism is more common among ... isn't as common as it might be. The researchers found ...
... of the New York state government has lashed out at ... as a shameful "chamber of filth, decay, indifference and danger." ... the agency has filed a suit in the federal court ... patients are subjected to overcrowded conditions, physical abuse and unnecessary ...
... the despicable practice of female feticide increased in India, there ... ,Five years ago the Indian Medical Association had ... aiding female feticide. No support would be extended to practitioners ... ,The Indian authorities are wrestling with the problem, and here ...
Cached Medicine News:Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:The DNA That Spells Double Risk of Heart Attack 2Health News:Who Receives a Kidney Transplant First? 2Health News:Spouse may "drive You to Drink" but also can Protect You from Alcohol 2Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2Health News:Now Sex Determination of Fetuses in Six Weeks in UK 2
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
... & Solutions offers a wide variety ... needs of healthcare professionals. Whether you ... prefer a dry scrub brush in ... brushes provide the flexibility and options ...
... of healthcare associated infections can be prevented with ... action a healthcare worker can do to reduce ... Alcohol gel hand sanitization is fast, easy to ... with soap and water. , Aplicare's 62% Ethyl ...
Medicine Products: